Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis

HPB

Volumn 14, Issue 1, 2012, Pages 60-66

  Shaheen, Mohammed ^a   Hassanain, Mazen ^a,b   Aljiffry, Murad ^a,c   Cabrera, Tatiana ^a   Chaudhury, Prosanto ^a   Simoneau, Eve ^a   Kongkaewpaisarn, Nuttawut ^a   Salman, Ayat ^a   Rivera, Juan ^a   Jamal, Mohammad ^a   Lisbona, Robert ^a   Khankan, Azzam ^a   Valenti, David ^a   Metrakos, Peter ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Liver; Non colorectal metastases < liver; Radiological intervention fluoroscopically guided < liver

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MICROSPHERE; OCTREOTIDE; TECHNETIUM 99M; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLUOROSCOPY; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE;

EID: 83555168147     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2011.00405.x     Document Type: Article

References (35)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, et al,. (2008) One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 26: 3063-3072.
2. Modlin I, Lye K, Kidd M,. (2003) A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97: 934-959. (Pubitemid 36173145)
3. Chan J, Kulke M,. (2009) Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep 11: 193-199.
4. Benevento A, Boni L, Frediani L, et al,. (2000) Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 74: 24-29. (Pubitemid 30387217)
5. Kalinowski M, Dressler M, König A, et al,. (2009) Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79: 137-142.
6. Oberg K,. (1999) Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol 10 (Suppl. 2): S3-S8. (Pubitemid 29288524)
7. Madoff D, Gupta S, Ahrar K, et al,. (2006) Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 17: 1235-1249. quiz 1250.
8. Stinner B, Kisker O, Zielke A, et al,. (1996) Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg 20: 183-188. (Pubitemid 26069484)
9. Kennedy A, Coldwell D, Nutting C, et al,. (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65: 412-425.
10. Kennedy A, Dezarn W, McNeillie P, et al,. (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31: 271-279.
11. King J, Quinn R, Glenn D, et al,. (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113: 921-929.
12. Rhee T, Lewandowski R, Liu D, et al,. (2008) 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247: 1029-1035. (Pubitemid 351770424)
13. Rinke A, Müller HH, Schade-Brittinger C, et al,. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656-4663.
14. Salem R, Thurston KG, Carr BI, et al,. (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13: S223-S229.
15. Lencioni R, Llovet JM,. (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60.
16. Veenendaal L, Borel Rinkes I, Lips C, et al,. (2006) Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 4: 35.
17. Cao CQ, Yan TD, Bester L, et al,. (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97: 537-543.
18. Ihse I, Persson B, Tibblin S,. (1995) Neuroendocrine metastases of the liver. World J Surg 19: 76-82.
19. Fendrich V, Michl P, Habbe N, et al,. (2010) Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2: 367-373.
20. Dong XD, Carr BI,. (2010) Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol; In press.
21. Shebani KO, Souba WW, Finkelstein DM, et al,. (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229: 815-821. discussion 822-813.
22. Chamberlain RS, Canes D, Brown KT, et al,. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432-445. (Pubitemid 30181109)
23. Murthy R, Nunez R, Szklaruk J, et al,. (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25 (Suppl. 1): S41-S55. (Pubitemid 41686061)
24. Gray B, Van Hazel G, Hope M, et al,. (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12: 1711-1720. (Pubitemid 34105661)
25. Carr B,. (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10: S107-S110. (Pubitemid 38240109)
26. Saxena A, Chua T, Bester L, et al,. (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251: 910-916.
27. Chamberlain R, Canes D, Brown K, et al,. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432-445. (Pubitemid 30181109)
28. Artale S, Giannetta L, Cerea G, et al,. (2005) Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Res 25: 4463-4469. (Pubitemid 41729497)
29. Bajetta E, Catena L, Procopio G, et al,. (2005) Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16: 1374-1380. (Pubitemid 41158484)
30. Panzuto F, Nasoni S, Falconi M, et al,. (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12: 1083-1092. (Pubitemid 41815799)
31. Rindi G, D'Adda T, Froio E, et al,. (2007) Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18: 145-149. (Pubitemid 351378063)
32. Frilling A, Li J, Malamutmann E, et al,. (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96: 175-184.
33. Durante C, Boukheris H, Dromain C, et al,. (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16: 585-597.
34. Sarmiento JM, Que FG,. (2003) Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12: 231-242. (Pubitemid 36210867)
35. Chung MH, Pisegna J, Spirt M, et al,. (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130: 954-962. (Pubitemid 34014560)